Ruti Aga's Six-Year Ban: Two Years for the Drug, Four for a Prescription No Clinic Ever Issued

Ruti Aga won a half marathon in China in March. The results sheet carries her name at the top and no time beside it. The Athletics Integrity Unit's statement on Thursday does not carry a time either. What it carries is the number six — two years for the presence of methylprednisolone, four years for a prescription issued by a man with no medical registration, who claimed he had used "an old prescription pad from a former workplace." The clinic did not exist.

Context

Aga is 32. The AIU statement records a 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. My own road-racing database has Berlin 2026 (2:18:34, second) and Tokyo 2026 (2:20:40, first), but those figures come from my columns, not from the AIU statement, so treat them as pending verification. The confirmed fact is that a sample taken after her March win in China returned methylprednisolone.

The decision separates two violations. Presence of a prohibited substance: two years. Tampering: four years. Total six, effective from 10 September, the same date her provisional suspension began. The statement does not state the year, so I am leaving the year unspecified rather than inventing one.

The classification error that distorts the case

The reporting calls methylprednisolone a "prohibited steroid" and says WADA classifies it as performance enhancing. That is technically wrong, and the error blurs the entire legal structure of the case. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (S1). Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection out of competition is entirely legal.

The technical detail missing from every version of this story: a road race's in-competition testing window opens at 23:59 the day before the race. An injection given days earlier can still be caught if residues remain. Intra-articular methylprednisolone for knee synovitis is standard sports-medicine practice in marathon runners. A genuine documentary record would have left a legitimate defence open — route, timing, medical necessity.

That route was closed not by the drug but by the paper.

Three independent verification failures

One: the prescriber was a family member with no registration. Two: the clinic named on the prescription did not exist. Three: the defence claimed an old pad from a former workplace, and the clinic explicitly disowned the claim. A single phone call, email or registry check would have collapsed the document. None happened. That is no longer an oversight; it is a design.

A forged prescription is not evidence of treatment. It is evidence of the absence of treatment. With real records, any competent lawyer hands over the file on day one, clarifies TUE status, and the case ends below two years or disappears.

Decoding the arithmetic

Two years for presence is the standard sanction for a category of substance where intent is not proven. Four years for tampering is the Code's standard sanction. The sum tells us the panel rejected the no-significant-fault mitigation that would have reduced the presence sanction. Backdating to 10 September is procedural benefit, not leniency — the athlete had already lost those months. A CAS appeal window exists, typically around 21 days, but document-based findings are hard to overturn.

What matters is that four of the six years were bought by a piece of paper.

The knee is the cause; the prescription is the symptom

No registered team physician appears. No TUE process. No washout calculation. The man described as a doctor had neither registration nor clinic. This is the signature of an athlete operating without credentialed medical support.

Russia taught me this: the detour is not noise; it is the first honest signal. The forged prescription reads as the end of the story. Plotted against the entourage, it is the beginning — it shows where the treatment came from and who judged it risk-free. The tampering charge also arises from an interview, not a document. Language and translation conditions in AIU interviews with East African athletes remain a recurring point of contention.

Age curve and Ethiopian depth

At 32, a six-year ban returns her at roughly 38. Ethiopian women's marathon depth is such that a 2:18–2:20 performer is not automatically selectable. Elite-career-wise, six years is a lifetime ban. The 2026 Tokyo title and three Major second places remain the record of a genuinely elite athlete; the statement does not specify the disqualification scope. Commercially, she is now radioactive in a sport where distance-running sponsorship is already thin — global brands buy exposure ROI, not this kind of exposure.

The China label circuit

Asia's label-race tier is the income band between Majors for East African marathoners: modest competitive pressure, good appearance fees, few races. It is also the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are now colliding in the same races. That does not mean more cheating there; it means someone is finally looking.

In 2026 in London I built a side screen of 2,900 players across 14 second-tier European leagues with a hard 900-minute floor and minutes-adjusted xG+xA. It surfaced a 19-year-old Danish midfielder nobody had listed. Since that day I do not write "in form" without a sample size. So here: the sample size of this case is one athlete, one prescription, one clinic that did not exist. Print that caveat in the same sentence.

Contrarian: state the consensus, then break it

The popular reading is that a great runner doped and got six years. The alternative reading is that six years for a glucocorticoid is disproportionate enforcement against African road runners.

Neither survives the numbers. The six years is not the price of the substance; the arithmetic prices the substance at two. The other four belong to a separate offence. Anyone writing "six years for a glucocorticoid" is making the same error as the report that called it a steroid — skipping the middle step to land on the outcome. And the disproportionality argument only works if the sanction came from the drug. It came from the document, and the document rule is written identically for everyone.

The genuinely uncomfortable point is different: her strongest defence — the drug was legitimate, the timing was wrong — actually existed. Because S9 is in-competition only, correct route and timing with real records could have produced zero. What closed that path was a family member reaching for an old pad.

Takeaway

The question is not when Aga returns; at 38, inside Ethiopian depth, that question has closed itself. The question is how many athletes in the same training cluster are served by the same informal medical network — that pad was not manufactured for one person. And the question nobody asked: what happened to the agent or manager who saw, accepted or forwarded the document? The statement does not name one. Perhaps the investigation never went there.